Chronic Constrictive Pericarditis Induced by Long-Term Bromocriptine Therapy: Report of Two Cases

Champagne, Stéphane; Coste, E; Peyrière, Hélène; Nigond, J; Mania, Emile; Pons, Maxime; Hillaire‐Buys, Dominique; Balmès, P; Blayac, Jean-Pierre; Davy, Jean‐Marc

doi:10.1345/aph.18461

Cited by 16 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psychotic reactions peaked in 2009 then declined, which correlated with decreased cabergoline and increased pramipexole use. The association of long-term therapy with ergot-derived DAs and fibrotic reactions is well recognised [ 17 – 19 ], with a peak of reports in 2005 and subsequent decline. It is difficult to determine whether the fewer reports reflect the steady decline in prescribing of bromocriptine since the 1990s, or cabergoline, or both.…”

Section: Resultsmentioning

confidence: 99%

Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia

Hollingworth

McGuire

Pache

et al. 2015

Drugs - Real World Outcomes

View full text Add to dashboard Cite

BackgroundIn Australia, there is voluntary reporting of suspected adverse events (AEs) of therapeutic medicines. Some dopamine agonists (DAs) have serious AEs.ObjectiveWe aimed to explore the pattern of DA AE reporting over two decades.MethodsWe analysed AE case line listings obtained from the Australian Committee on the Safety of Medicines (ACSOM) for bromocriptine, cabergoline, pergolide, pramipexole and ropinirole, and related these to drug utilisation data (1992–2012). We noted the AE nature, frequency, onset, novelty, severity and outcome.ResultsThe 220 suspected AEs fell into five categories: (i) syncopal/pre-syncopal, (ii) fibrotic, (iii) psychotic, (iv) obsessive-compulsive behaviours (OCB) and (v) increased sleep. There were differential lag times between initial individual drug registration and reporting of suspected AEs, with a lag of at least one year for fibrotic reactions and OCB compared to more contemporaneous reporting of other AEs. Consistent with the published literature, ACSOM data showed that ergot DAs share fibrotic reactions as a class AE, whereas symptomatic hypotensive reactions, psychosis and OCB occurred in both ergot and non-ergot DAs, cabergoline and pramipexole, respectively. Reports of syncopal and pre-syncopal reactions seemed to diminish as ergot-based DA use declined. Levodopa was taken simultaneously with DAs in 87 instances. Of those treated, 92 % were 50 years or older. Parkinson’s disease accounted for 89 % of use (119 reports).ConclusionsExploring the temporal relationship between post-marketing AE reporting and utilisation data, as exemplified by DAs, can be a valuable pharmacovigilance tool to encourage targeted adverse event monitoring and reporting.

show abstract

Section: Resultsmentioning

confidence: 99%

Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia

Hollingworth

McGuire

Pache

et al. 2015

Drugs - Real World Outcomes

View full text Add to dashboard Cite

show abstract

“…1 CHF, constrictive pericarditis, and severe pleuropulmonary inflammatory—fibrotic syndrome have been reported with cabergoline (another dopamine agonist used in the treatment of Parkinson's disease as well as prolactinomas) therapy. 2 Although constrictive pericarditis has been reported with bromocriptine therapy, 3 To the best of our knowledge, no case reports of severe, reversible DCMP with bromocriptine therapy are available in the literature.…”

Section: Discussionmentioning

confidence: 99%

Acute Onset of Severe Dilated Cardiomyopathy During Bromocriptine Therapy

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Its AEs include profi brotic activity affecting various parts of the body (heart valves, retroperitoneum, lungs, and pleura, pericardium). Pericardial fi brosis can progress to constrictive pericarditis, 66 which occurs rarely and is listed, e.g., in its SmPC. Pericarditis can also be induced by other substances of this class of drugs such as lisuride, cabergoline, pergolide, and the antimigraine agent methylsergide.…”

Section: Ergot Derivativesmentioning

confidence: 99%

Drug-induced pericarditis

Alušík¹,

Paluch²

2022

Cor Vasa

View full text Add to dashboard Cite

Léky vyvolané perikarditidy nejsou časté, ale závažné onemocnění, protože případná tamponáda perikardu může ohrozit život pacienta. Vzhledem k tomu, že nabídka nových léků se neustále rozšiřuje, zvyšuje se i podíl léčiv schopných perikarditidu vyvolat. Autoři vyhodnotili práce s touto tematikou uvedené v databázi PubMed a doplnili informacemi z databáze VigiBase. Ve svém článku autoři uvádějí současné poznatky o mechanismech vzniku i stupni rizika vzniku léky vyvolané perikarditidy. Uvádějí relevantní informace o jednotlivých lécích rozdělených do sedmi skupin. U některých léčiv je riziko vzniku perikarditidy vysoké a při léčbě těmito přípravky je nutné toto riziko brát v úvahu.

show abstract

Chronic Constrictive Pericarditis Induced by Long-Term Bromocriptine Therapy: Report of Two Cases

Abstract: Our cases call attention to a possible association between bromocriptine use in patients who have Parkinson's disease and constrictive pericarditis.

Cited by 16 publications

References 11 publications

Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia

Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia

Acute Onset of Severe Dilated Cardiomyopathy During Bromocriptine Therapy

Drug-induced pericarditis

Contact Info

Product

Resources

About